Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Russian Academy of Medical Sciences
• Treatments: Eculizumab

Criteria

Inclusion Criteria:

1. age 1-80

2. weight - >6 kg

3. male or female

4. recipient of first kidney graft either from standard criteria deceased or live donor

5. end stage renal disease or congenital nephrotic syndrome -

Exclusion Criteria:

1. Blood group (ABO) incompatible transplantation

2. presence of donor-specific anti-human leukocyte antigen (HLA) antibodies

3. multiorgan transplantation

4. previous transplant

5. patients infected with HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)

6. patients with haemolytic-uraemic syndrome (HUS) -